Why the study?
Does SERCA2a gene therapy improve outcomes in patients with heart failure?
Does SERCA2a gene therapy improve outcomes in patients with heart failure?
This review highlights the potential of SERCA2a gene therapy as a novel treatment for heart failure with both inotropic and anti-arrhythmic properties.
Gene therapy has been applied to cardiovascular disease for over 20 years but it is the application to heart failure that has generated recent interest in clinical trials. There is laboratory and early clinical evidence that delivery of sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy is beneficial for heart failure and this therapy could become the first positive inotrope with anti-arrhythmic properties. In this review we will discuss the rationale for SERCA2a gene therapy as a viable strategy in heart failure, review the published data, and discuss the ongoing clinical trials, before concluding with comments on the future challenges and potential for this therapy.
No takes yet. Share an insight, caveat, or question.
Hayward et al. (2015) conducted a review in Heart failure. SERCA2a gene therapy was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: